On Tuesday, H.C. Wainwright maintained a Buy rating on Arcturus Therapeutics (NASDAQ:ARCT), with a steady price target of $60. The firm's endorsement follows Arcturus Therapeutics' recent announcement regarding its progress on ARCT-032, an inhaled mRNA treatment candidate for cystic fibrosis (CF), and ARCT-810, an mRNA-based therapeutic for ornithine transcarbamylase (OTC) deficiency.
Arcturus revealed its intention to submit an Investigational New Drug (IND) application for ARCT-032 within the coming 60 days. This submission aims to kick-start a Phase 2 multiple ascending dose (MAD) study. The decision is backed by positive safety and tolerability data gathered from a group of healthy volunteers and the ongoing Phase 1b study.
The upcoming Phase 2 study for ARCT-032 is designed to pinpoint a safe and efficacious dosage for CF patients who do not respond to cystic fibrosis transmembrane conductance regulator (CFTR) modulators. These patients represent a subset of the CF population with either dysfunctional or absent CFTR protein or intolerance to current CFTR modulator therapies.
Notably, Arcturus has reported promising interim results from its Phase 1b study. The company is preparing to administer the treatment to the seventh and final participant soon. Highlighting the potential of ARCT-032, Arcturus disclosed that a patient with Class I mutations and low baseline lung function experienced a 4% improvement in lung capacity following two doses of the treatment.
Beyond the advancements in its CF treatment, Arcturus is also looking forward to the anticipated third-quarter 2024 market launch of its mRNA COVID-19 vaccine, Kostaive, in Japan through a partnership with Meiji Seika Pharma, a subsidiary of Meiji Holdings. H.C. Wainwright's positive outlook on Arcturus is bolstered by the potential of its wholly-owned rare disease programs, including both ARCT-032 and ARCT-810.
In other recent news, Arcturus Therapeutics Holdings Inc. has made significant progress in its clinical programs for ARCT-810 and ARCT-032, targeting rare diseases ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), respectively. The company reported a net loss of $26.8 million for Q1 2024 and announced the appointment of Dr. Moncef Slaoui to its Board of Directors.
Investment firms Piper Sandler and Citi have maintained their positive ratings on Arcturus, influenced by promising Phase 1b trial results and the anticipation of significant developments in the company's four main programs. ARK ETFs, managed by Cathie Wood, acquired 58,363 shares of Arcturus, signaling a strengthening position in the company's portfolio.
InvestingPro Insights
As Arcturus Therapeutics (NASDAQ:ARCT) continues to progress with its mRNA treatment candidates, it's essential for investors to consider the financial health and market sentiment surrounding the company. According to InvestingPro data, Arcturus holds a market capitalization of $637.21 million, indicating a relatively small-cap presence in the biotech sector. The company's P/E ratio stands at -5.92, reflecting market skepticism about its profitability in the near term. This caution is further underscored by a substantial decline in revenue over the last twelve months as of Q1 2024, with a reported decrease of -55.69%. Despite these challenging financial metrics, Arcturus holds more cash than debt on its balance sheet, which could provide some financial flexibility as it moves forward with clinical trials and product development.
Investors should note that Arcturus's stock price has experienced significant volatility, with a -39.04% total return over the past month. This could be attributed to the broader market dynamics or specific concerns about the company's pipeline and earnings potential. While the stock has taken a notable hit, there are signs of resilience, such as the company's liquid assets exceeding short-term obligations, which may provide a cushion against immediate financial pressures.
For those seeking a deeper dive into Arcturus's prospects, InvestingPro offers additional insights and analysis. There are 11 additional InvestingPro Tips available, which could help investors make more informed decisions. For access to these tips and more comprehensive data, consider using the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.